{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:06Z","timestamp":1783641606489,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.pnpbp.2018.04.014","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T12:43:20Z","timestamp":1524660200000},"page":"116-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Reduced clearance of venlafaxine in a combined treatment with quetiapine"],"prefix":"10.1016","volume":"85","author":[{"given":"Michael","family":"Paulzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-0307","authenticated-orcid":false,"given":"Marc","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pnpbp.2018.04.014_bb0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0165-1781(00)00213-4","article-title":"Effect of venlafaxine on imipramine metabolism","volume":"96","author":"Albers","year":"2000","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.04.014_bb0010","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/009127009903900314","article-title":"Effect of venlafaxine on the pharmacokinetics of risperidone","volume":"39","author":"Amchin","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2018.04.014_bb0015","author":"AstraZeneca"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.04.014_bb0020","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.1365-2125.1997.00591.x","article-title":"Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2","volume":"43","author":"Ball","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2018.04.014_bb0025","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3109\/15622975.2013.804195","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders","volume":"14","author":"Bauer","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.04.014_bb0030","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.pnpbp.2018.04.014_bb0035","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.v68n1011","article-title":"Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service","volume":"68","author":"Castberg","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"9665","key":"10.1016\/j.pnpbp.2018.04.014_bb0040","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.pnpbp.2018.04.014_bb0045","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/hup.963","article-title":"Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates","volume":"23","author":"Dannlowski","year":"2008","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.014_bb0050","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/jpet.106.103382","article-title":"Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor","volume":"318","author":"Deecher","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.014_bb0055","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pnpbp.2008.09.026","article-title":"Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release","volume":"33","author":"Figueroa","year":"2009","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2018.04.014_bb0060","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1592\/phco.22.16.1500.33697","article-title":"Elevation of carbamazepine-10,11-epoxide by quetiapine","volume":"22","author":"Fitzgerald","year":"2002","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.pnpbp.2018.04.014_bb0065","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0893-133X(98)00113-4","article-title":"O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants","volume":"20","author":"Fogelman","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.014_bb0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Ther. Drug Monit."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.04.014_bb0075","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jad.2011.10.033","article-title":"Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009","volume":"136","author":"Greil","year":"2012","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.04.014_bb0080","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/15622975.2013.770551","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder","volume":"14","author":"Grunze","year":"2013","journal-title":"World J Biol Psychiatry"},{"issue":"3\u20134","key":"10.1016\/j.pnpbp.2018.04.014_bb0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1515\/DMDI.2006.21.3-4.187","article-title":"In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions","volume":"21","author":"Hasselstrom","year":"2006","journal-title":"Drug Metabol. Drug Interact."},{"issue":"1\u221202","key":"10.1016\/j.pnpbp.2018.04.014_bb0090","first-page":"9","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.04.014_bb0095","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/JCP.0000000000000576","article-title":"Interaction between risperidone, venlafaxine, and metronidazole: an unknown thread","volume":"36","author":"Hovancakova","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.014_bb0100","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/tpj.2014.50","article-title":"Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases","volume":"15","author":"Karlsson","year":"2015","journal-title":"Pharmacogenomics J"},{"issue":"8","key":"10.1016\/j.pnpbp.2018.04.014_bb0105","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/j.1552-4604.1992.tb03875.x","article-title":"Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite","volume":"32","author":"Klamerus","year":"1992","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2018.04.014_bb0110","first-page":"02","article-title":"Effects of the proton pump inhibitors omeprazole and pantoprazole on the cytochrome P450-mediated metabolism of venlafaxine","author":"Kuzin","year":"2017","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.014_bb0115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1515\/dmdi-2014-0011","article-title":"Clinical drug-drug interactions: focus on venlafaxine","volume":"30","author":"Magalhaes","year":"2015","journal-title":"Drug Metabol. Personal. Ther."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.014_bb0120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/FTD.0000000000000251","article-title":"Risperidone and venlafaxine metabolic ratios strongly predict a CYP2D6 poor metabolizing genotype","volume":"38","author":"Mannheimer","year":"2016","journal-title":"Ther. Drug Monit."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.04.014_bb0125","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/01.jcp.0000144894.37611.0a","article-title":"Venlafaxine for the treatment of depressive episode during the course of schizophrenia","volume":"24","author":"Mazeh","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.014_bb0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/FTD.0b013e3181fcf94d","article-title":"Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine","volume":"33","author":"McAlpine","year":"2011","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.014_bb0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/JCP.0b013e3182a95af2","article-title":"Restless legs syndrome associated with the combined use of quetiapine and venlafaxine","volume":"34","author":"Michopoulos","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2018.04.014_bb0140","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1176\/appi.ajp.2016.16050523","article-title":"Morbidity and mortality associated with medications used in the treatment of depression: an analysis of cases reported to U.S. poison control centers, 2000-2014","volume":"174","author":"Nelson","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.014_bb0145","first-page":"47","article-title":"Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities","volume":"42","author":"Oganesian","year":"2009","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.pnpbp.2018.04.014_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.psyneuen.2016.07.009","article-title":"Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; a pharmacokinetics-based hypothesis","volume":"73","author":"Paulzen","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2018.04.014_bb0155","first-page":"01","article-title":"Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns","author":"Paulzen","year":"2016","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.04.014_bb0160","doi-asserted-by":"crossref","first-page":"301e9","DOI":"10.1016\/j.genhosppsych.2010.11.015","article-title":"Serotonin syndrome associated with polypharmacy in the elderly","volume":"33","author":"Poeschla","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.014_bb0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1345\/aph.1E073","article-title":"Multiple complications and withdrawal syndrome associated with quetiapine\/venlafaxine intoxication","volume":"39","author":"Precourt","year":"2005","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.014_bb0170","first-page":"99","article-title":"Interactions between the cytochrome P450 system and the second-generation antipsychotics","volume":"28","author":"Prior","year":"2003","journal-title":"J. Psychiatry Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.014_bb0175","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/FTD.0b013e31819114ea","article-title":"Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database","volume":"31","author":"Reis","year":"2009","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.04.014_bb0180","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-3565(25)12326-4","article-title":"Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine","volume":"276","author":"Ring","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2018.04.014_bb0185","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/YIC.0000000000000131","article-title":"Risperidone induced extrapyramidal side effects \u2013 is the need for anticholinergics the consequence of high plasma concentrations?","volume":"31","author":"Schoretsanitis","year":"2016","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.pnpbp.2018.04.014_bb0190","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-016-2085-2","article-title":"Pharmacokinetic patterns of risperidone-associated adverse drug reactions","volume":"72","author":"Schoretsanitis","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2018.04.014_bb0195","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2710.2006.00763.x","article-title":"CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine","volume":"31","author":"Shams","year":"2006","journal-title":"J. Clin. Pharm. Ther."},{"issue":"5","key":"10.1016\/j.pnpbp.2018.04.014_bb0200","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00702-014-1317-9","article-title":"Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI","volume":"122","author":"Sigurdsson","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"10.1016\/j.pnpbp.2018.04.014_bb0205","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.2016.1154043","article-title":"Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics","volume":"12","author":"Spina","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"4\u20135","key":"10.1016\/j.pnpbp.2018.04.014_bb0210","first-page":"174","article-title":"Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring","volume":"47","author":"Stamm","year":"2014","journal-title":"Pharmacopsychiatry"},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.04.014_bb0215","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.schres.2015.10.021","article-title":"Serum level of venlafaxine is associated with better memory in psychotic disorders","volume":"169","author":"Steen","year":"2015","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.014_bb0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/clpt.1994.95","article-title":"The effect of renal disease on the disposition of venlafaxine","volume":"56","author":"Troy","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2018.04.014_bb0225","author":"U.S. Food and Drug Administration"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.04.014_bb0230","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-0031-1301366","article-title":"The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions","volume":"45","author":"Unterecker","year":"2012","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.014_bb0235","doi-asserted-by":"crossref","first-page":"76","DOI":"10.18553\/jmcp.2014.20.1.76","article-title":"Comparative assessment of adherence measures and resource use in SSRI\/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy","volume":"20","author":"Wade","year":"2014","journal-title":"J. Manag. Care Pharm."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.04.014_bb0240","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1600-0447.2009.01464.x","article-title":"Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine","volume":"121","author":"Wijkstra","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.04.014_bb0245","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/2045125312464386","article-title":"Neuroleptic malignant syndrome associated with quetiapine and venlafaxine use: a case report and discussion","volume":"3","author":"Woods","year":"2013","journal-title":"Ther Adv Psychopharmacol"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584618300460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584618300460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T22:54:03Z","timestamp":1751583243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584618300460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":49,"alternative-id":["S0278584618300460"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.04.014","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced clearance of venlafaxine in a combined treatment with quetiapine","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}